Basic Concepts in Dose-Finding

Statistical Methods for Dose-Finding Experiments

Volumn , Issue , 2006, Pages 3-18

  Chevret, Sylvie ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

dose, response and optimal dose; Dose finding experiments; Dose finding phase I trials; Dose finding trials; Dose response relationship; Escalating and de escalating dose levels; Maximum tolerated dose (MTD); Safe starting dose in human testing

Indexed keywords

DOSE FINDING; DOSE LEVELS; DOSE RESPONSE RELATIONSHIPS; DOSE, RESPONSE AND OPTIMAL DOSE; HUMAN TESTING; MAXIMUM TOLERATED DOSE; PHASE I;

EID: 70449679540     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470861258.ch1     Document Type: Chapter

References (54)

1. J. Kotz, Z. Knapik, W. Lubczynska-Kowalska, M. Houszka, J. Lapinska and M. Rybak (1988) Effect of a single dosis of 96%ethanol on rat gastric mucosa. Part I. Morphological studies. Mater. Med. Policy, 20(2), 67-9.
2. P.R. Freeman (1970) Optimal Bayesian sequential estimation of the median effective dose. Biometrika, 57, 79-89.
3. M. Mendoza (1990) A Bayesian analysis of the slope ratio bioassay. Biometrics, 46 (4), 1059-69.
4. F.L. Ramsey (1972) A Bayesian approach to bioassay. Biometrics, 28 (3), 841-58.
5. R. K. Tsutakawa (1972) Design of experiment for bioassay. J. Am. Statist. Assoc. 67, 584-90.
6. J.R. Murphy and D.L. Hall (1997) A logistic dose-ranging method for phase I clinical investigations trials. J. Biopharm. Statistics, 7(4), 635-47.
7. B.E. Storer (2001) Phase I trials, in Biostatistics in Clinical Trials (eds C. Redmond and T. Colton), John Wiley & Sons, Ltd, Chichester, pp. 337-42.
8. G. Emilien, W. van Meurs and J.M. Maloteaux (2000) The dose-response relationship in phase I clinical trial design and beyond: use, meaning and assessment. Pharmacology and Therapeutics, 88, 33-58.
9. D.D. Von Hoff, J. Kuhn and G.M. Clark (1984) Design and conduct of phase I trials, in Cancer Clinical Trials: Methods and Practice (eds M.E. Buyse, M.J. Staquet and R.J. Sylvester), Oxford University Press, Oxford, pp. 210-20.
10. ASCO (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology, J. Clin. Oncology, 15 (8), 2996-3018.
11. M.J. Ratain, R. Mick, R.L. Schilsky and M. Siegler (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl Cancer Inst., 85(20), 1637-43.
12. C. Gatsonis and J.B. Greenhouse (1992) Bayesian methods for phase I clinical trials. Statistics in Medicine, 11(10), 1377-89.
13. R. Simon, B. Freidlin, L. Rubinstein, S.G. Arbuck, J. Collins and M.C. Christian (1997) Accelerated titration designs for phase I clinical trials in oncology. J. Natl Cancer Inst., 89(15), 1138-47.
14. J.M. Collins, D.S. Zaharko, R.L. Dedrick and B.A. Chabner (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treatment Rep., 70(1), 73-80.
15. M. Agrawal and E.J. Emanuel (2003) Ethics of phase 1 oncology studies. JAMA, 290(8), 1075-82.
16. I. Mahmood (2001) Interspecies scaling of maximum tolerated dose of anticancer drugs: relevance to starting dose for phase I trials. Am. J. Therapeutics, 8(2), 109-16.
17. E.J. Freireich, E.A. Gehan, D.P. Rall, L.H. Schmidt and H.E. Skipper (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Rep., 50(4), 219-44.
18. D.J. Prieur, D.M. Young, R.D. Davis, D.A. Cooney, E.R. Homan, R.L. Dixon and A.M. Guarino (1973) Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology. Cancer Chemotherapy Rep. 3, 4(1), 1-39.
19. J.S. Penta, M. Rozencweig, A.M. Guarino and F.M. Muggia (1979) Mouse and largeanimal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemotherapy and Pharmacology, 3(2), 97-101.
20. M. Rozencweig, D.D. Von Hoff, M.J. Staquet, P.S. Schein, J.S. Penta, A. Goldin, F.M. Muggia, E.J. Freireich and V.T. DeVita Jr (1981) Animal toxicology for early clinical trials with anticancer agents. Cancer Clin. Trials, 4(1), 21-8.
21. E.A. Eisenhauer, P.J. O'Dwyer, M. Christian and J.S. Humphrey (2000) Phase I clinical trial design in cancer drug development. J. Clin. Oncology, 18(3), 684-92.
22. M.A. Goldsmith, M. Slavik and S.K. Carter (1975) Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res., 35(5), 1354-64.
23. H.H. Hansen, O.S. Selawry, F.M. Muggia and M.D. Walker (1970) Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (nsc 79037). Cancer Res., 31(3), 223-7.
24. W.F. Rosenberger and L.M. Haines (2002) Competing designs for phase I clinical trials: a review. Statistics in Medicine, 21(18), 2757-70.
25. Y. Lin andW.J. Shih (2001) Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics, 2(2), 203-15.
26. M. Stylianou and N. Flournoy (2002) Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics, 58(1), 171-7.
27. J.S. Penta, G.L. Rosner and D.L. Trump (1992) Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemotherapy and Pharmacology, 31(3), 247-50.
28. T.L. Smith, J.J. Lee, H.M. Kantarjian, S.S. Legha and M.N. Raber (1996) Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J. Clin. Oncology, 14(1), 287-95.
29. J.M. Collins, C.K. Grieshaber and B.A. Chabner (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl Cancer Inst., 82(16), 1321-26.
30. D.M. Potter (2002) Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Statistics in Medicine, 21 (13), 1805-23.
31. L.M. Haines, I. Perevozskaya and W.F. Rosenberger (2003) Bayesian optimal designs for phase I clinical trials. Biometrics, 59(3), 591-600.
32. W.M. Hryniuk (1988) More is better. J. Clin. Oncology, 6(9), 1365-7.
33. J. Babb, A. Rogatko and S. Zacks (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine, 17(10), 1103-20.
34. J. O'Quigley, M. Pepe and L. Fisher (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics, 46(1), 33-48.
35. J. Berkson (1944) Applications of the logistic function to bio-assay. J. Am. Statist. Assoc., 39, 357-65.
36. J. Whitehead and H. Brunier (1995) Bayesian decision procedures for dose determining experiments. Statistics in Medicine, 14(9), 885-93.
37. Y.K. Cheung and R. Chappell (2002) A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics, 58(3), 671-4.
38. S.D. Durham, and N. Flournoy (1994) Random walks for quantile estimation, in Statistical Decision Theory and Related Topics V (eds S.S. Gupta and J.O. Berger ), Springer, New York, pp. 467-76.
39. M. Gasparini and J. Eisele (2000) A curve-free method for phase I clinical trials. Biometrics, 56(2), 609-15.
40. J. O'Quigley (2002) Curve-free and model-based continual reassessment method designs. Biometrics, 58(1), 245-9.
41. J. O'Quigley, X. Paoletti and J. Maccario (2002) Non-parametric optimal design in dose finding studies. Biostatistics, 3(1), 51-6.
42. S.N. Goodman, M.L. Zahurak and S. Piantadosi (1995) Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine, 14(11), 1149-61.
43. E.L. Korn, D. Midthune, T.T. Chen, L.V. Rubinstein, M.C. Christian and R.M. Simon (1994) A comparison of two phase I trial designs. Statistics in Medicine, 13(18), 1799-806.
44. S. Moller (1995) An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine, 14(9-10), 911-22.
45. B.E. Storer (1989) Design and analysis of phase I clinical trial. Biometrics, 45(3), 925-37.
46. P.F. Thall, J.J. Lee, C.H. Tseng and E.H. Estey (1999) Accrual strategies for phase I trials with delayed patient outcome. Statistics in Medicine, 18(10), 1155-69.
47. N.L. Geller (1984) Design of phase I and II clinical trials in cancer: a statistician's view. Cancer Invest., 2(6), 483-91.
48. B.N. Bekele and Y. Shen (2004) A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Technical report, M. D. Anderson Cancer Center, The University of Texas.
49. A.T.R. Legedza and J.G. Ibrahim (2001) Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. Statistics in Medicine, 20(6), 867-82.
50. D.H. Leung and Y.G. Wang (2002) An extension of the continual reassessment method using decision theory. Statistics in Medicine, 21(1), 51-63.
51. E.L. Korn, S.G. Arbuck, J.M. Pluda, R. Simon, R.S. Kaplan and M.C. Christian (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncology, 19(1), 265-72.
52. S.G. Arbuck (1996) Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann. Oncology, 7(6), 567-73.
53. W.R. Parulekar and E.A. Eisenhauer (2004) Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl Cancer Inst., 96(13), 990-7.
54. S.F. Dent and E.A. Eisenhauer (1996) Phase I trial design: are new methodologies being put into practice? Ann. Oncology, 7(6), 561-6.